Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-CEA/B7.1 Vaccine With Chemotherapy in Metastatic Colorectal Cancer
NCT00027833Phase 2Unknown
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- Dec 2001
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ALVAC-CEA/B7.1 in colorectal cancer (CRC) (3 arms), sponsored by Herbert Irving Comprehensive Cancer Center. Primary endpoints: Safety and Tolerability and Immune Response. Status: unknown.
02
Drugs
ALVAC-CEA/B7.1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00027833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027833.